Plasma olanzapine in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1999-2009

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 411-417

  Patel, Maxine X ^a   Bowskill, Sally ^b   Couchman, Lewis ^b   Lay, Victoria ^b   Taylor, David ^c   Spencer, Edgar Pathrose ^d   Flanagan, Robert James ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

olanzapine: adherence; olanzapine: dose prediction; olanzapine: dose plasma concentration relationship; olanzapine: therapeutic drug monitoring

Indexed keywords

OLANZAPINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CHILD; DRUG INTERACTION; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PATIENT COMPLIANCE; PLASMA; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SEX; SMOKING; TOXICITY; VARIANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZODIAZEPINES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; YOUNG ADULT;

EID: 79960596183     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318221b408     Document Type: Article

References (44)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
2. Erratum: N Engl J Med. 2010;363:1092-1093.
3. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097. (Pubitemid 351418005)
4. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
5. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
6. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911-936. (Pubitemid 47557106)
7. Flanagan RJ. Side-effects of clozapine and some other psychoactive drugs. Current Drug Saf. 2008;3:115-122.
8. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008;7:761-769.
9. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
10. Kassahun K, Mattiuz E, Franklin R, et al. Olanzapine 10-N-glucuronide. A tertiary N-glucuronide unique to humans. Drug Metab Dispos. 1998;26:848-855. (Pubitemid 28452050)
11. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20. (Pubitemid 32096745)
12. Bigos KL, Pollock BG, Coley KC, et al. Sex, race and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157-165.
13. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280-291.
14. Rao ML, Hiemke C, Grasmader K, et al. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring.] Fortschr Neurol Psychiatry. 2001;69:510-517. (Pubitemid 33086201)
15. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 10th ed. London, UK: Informa Healthcare; 2009.
16. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-928. (Pubitemid 28307604)
17. Flanagan RJ, Harvey EJ, Spencer EP. HPLC of basic drugs on microparticulate strong cation-exchange materials. Forensic Sci Int. 2001;121:97-102. (Pubitemid 32758818)
18. FDA/CDER (Food and Drug Administration/Center for Drug Evaluation and Research) Guidance for industry. Bioanalytical method validation. 2001. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed May 11, 2011.
19. Clinical and Laboratory Standards Institute. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. Edition 2. Document EP05-A 2, 2004. Available at: http://webstore.ansi.org/ansidocstore/ product.asp?sku=EP05%2DA2. Accessed May 11, 2011.
20. Green M, Mougey B, Wildgust HJ. Overdose following therapeutic drug monitoring in schizophrenia. Prog Neurol Psychiatry. 2008;12:11-12.
21. British National Formulary Edition 60. London, UK: BMJ Group/Pharmaceutical Press; 2010.
22. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20:55-60. (Pubitemid 40092392)
23. Kelly DL, Richardson CM, Yu Y, et al. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol. 2006;21:393-398. (Pubitemid 44355618)
24. Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultra-violet detection considering the oxidability of the compound and presence of other psychotropic drugs. J Chromatogr B. 1998;714:309-315. (Pubitemid 28386853)
25. Heller S, Hiemke C, Stroba G, et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Ther Drug Monit. 2004;26:459-461. (Pubitemid 38989668)
26. Dusci LJ, Hackett LP, Fellows LM, et al. Determination of olanzapine in plasma by high-performance liquid chromatography using ultra-violet absorbance detection. J Chromatogr B. 2002;773:191-197. (Pubitemid 34595392)
27. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
28. Mitchell M, Riesenberg R, Bari MA, et al. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin Ther. 2006;28:881-892. (Pubitemid 44062696)
29. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-526. (Pubitemid 34857906)
30. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53. (Pubitemid 36139825)
31. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63-68. (Pubitemid 38651019)
32. Citrome L, Stauffer VL, Chen L, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009;29:278-283.
33. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181-189.
34. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17:665-674.
35. Lobo ED, Robertson-Plouch C, Quinlan T, et al. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. Paediatr Drugs. 2010;12:201-211.
36. Zhou SF, Wang B, Yang LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010;42:268-354.
37. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010;44:727-732.
38. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324-1333. (Pubitemid 38989084)
39. Bigos KL, Pollock BG, Stankevich BA, et al. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6: 522-543.
40. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78. (Pubitemid 38134168)
41. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotenergic polymorphisms influence therapeutic outcome. Pharmacogenom J. 2010;10:20-29.
42. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psych Scand. 2010;122:440-441.
43. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol. 2002;17:141-143. (Pubitemid 34442196)
44. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392-400.